/
AGEN
$3.15+$0.12 (+3.96%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$126.2M
42M shares
52-week range
$2.71 – $7.34
10% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.92%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-108.05
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.8M | $150.0M | $88.2M | $295.7M | $98.0M | $156.3M | $103.5M | $114.2M |
| Cost of revenue | $124.6M | $168.3M | $145.0M | $182.1M | $197.3M | $237.7M | $156.0M | $80.4M |
| Gross profit | −$87.8M | −$18.3M | −$56.8M | $113.6M | −$99.2M | −$81.4M | −$52.6M | $33.8M |
| Gross margin | -238.7% | -12.2% | -64.4% | 38.4% | -101.2% | -52.1% | -50.8% | 29.6% |
| R&D | $124.6M | $168.3M | $142.6M | $178.6M | $0 | $234.6M | $155.5M | $0 |
| Operating income | −$123.8M | −$70.1M | −$117.2M | $25.7M | −$179.4M | −$159.5M | −$120.5M | −$20.6M |
| EBITDA | −$130.5M | −$63.4M | −$114.6M | $43.8M | −$161.8M | −$145.9M | −$101.3M | $62.2M |
| Net income | −$159.7M | −$107.7M | −$180.9M | −$23.9M | −$220.1M | −$245.8M | −$227.2M | $115.0K |
| Net margin | -434.1% | -71.7% | -205.2% | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% |
| EPS (diluted) | -28.83 | -22.10 | -21.00 | -2.11 | -15.64 | -13.75 | -10.59 | -0.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $136M | $0.79 | $0.69–$0.88 | 1 |
| 2027 | $138M | $-0.18 | $-0.20–$-0.16 | 1 |
| 2028 | $128M | $-0.56 | $-0.63–$-0.49 | 1 |
| 2029 | $138M | $-0.34 | $-0.38–$-0.30 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Agenus Inc.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
www.agenusbio.com- Employees
- 81
- IPO / List date
- Feb 4, 2000
- HQ
- LEXINGTON, MA
Held by traders on TradeandTell
No one on the platform currently holds AGEN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 285,646 | $954.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-04-12 | 1-for-20reverse |
| 2011-10-03 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded AGEN yet.
